The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion channels and optogenetics”. It was jointly presented to Karl Deisseroth, The Howard Hughes Medical Institute and Stanford University, USA; Peter Hegemann, Humboldt… Read More
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients. It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is… Read More
Johnson & Johnson has announced positive topline results from a Phase III study evaluating Caplyta (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder. The study met its primary endpoint, with Caplyta demonstrating a statistically significant and rapid… Read More
AstronauTx has received funding from The Michael J Fox Foundation for Parkinson’s Research (MJFF), while Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL). The MJFF-funded project, titled ‘Ligand-Gated Ion Channel Modulation as a Disease-Modifying Treatment for Prodromal Synucleinopathies’, will… Read More
Palomar Labs (formerly Negev Labs), a venture studio that builds companies around neuropsychiatric drug development programmes with prior human validation, has announced the spinout of Ariadne Bio, its first portfolio company. Ariadne Bio launches with lead programme AB-300, a clinical-stage-ready, non-hallucinogenic serotonin 2A receptor agonist in development… Read More
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases. The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed. VHB937… Read More
Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). Read More
Jack O’Meara CEO and Co-Founder of Aerska, compares the cardiovascular field to advances in neuroscience and how a preventative approach could be on the horizon for diseases such as Alzheimer’s. At Ochre Bio, the company I ran before Aerska, we spent years keeping human livers alive outside the body. Organs turned down for transplant, hooked up to… Read More
Scientists have mapped every connection in the brain and nerve cord of an adult male animal, unlocking insights into the neural mechanisms that shape behaviour. Known in scientific terms as a ‘connectome’, the team have produced a wiring map of the 166,700 neurons and the millions of connections between them. Read More
Biohaven and SK Biopharmaceuticals have agreed a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven’s Kv7 ion channel platform. The platform is led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase II/III development… Read More
A group of charities have announced $3 million in grants to fund four innovative research projects over two years, stemming from the 2026 Tauopathy Challenge Workshop. The Rainwater Charitable Foundation, in collaboration with the Alzheimer’s Association, the Aging Mind Foundation, and CurePSP, will fund the proposals based… Read More
NRG Therapeutics has shared preclinical and mechanistic data of its lead clinical asset NRG5051, a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson’s. NRG disclosed that NRG5051, a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition… Read More
Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million). The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures. In… Read More
Cumulus Neuroscience, a global digital health company, has published final results from its first-in-class CNS-102 study in Scientific Reports. The study was conducted in collaboration with the PRECISIONALS initiative, a Research Ireland academic–industry collaboration hosted by Trinity College Dublin. The paper, titled “Longitudinal cognitive assessment using the Cumulus NeuLogiq Platform in… Read More
MindMaze Therapeutics has appointed Dr John Krakauer as a strategic advisor to support its next phase of growth in the United States. “John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery,” said Zach Henderson, CEO of MindMaze Therapeutics. “As… Read More
AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD). ACI-7104 is designed to induce… Read More
